STAR and Deferred Stenting Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-23

Study Completion Date

2025-08-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

STAR is a minimal-risk pragmatic clinical trial of patients admitted for a CTO-PCI procedure. The overall objective of the STAR Study is to address the current gaps in knowledge regarding use of STAR during CTO-PCI, as a prospective, multi-center study of 150 participants with randomization of timing of staged PCI. Five sites will be selected to participate in STAR from a national network of highly experienced CTO-PCI centers across the United States.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction

NCT01997294

Acute Myocardial Infarction

UNKNOWN NA

Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients

NCT01040936

Acute Coronary Syndrome

UNKNOWN PHASE4

Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI

NCT01293097

Non-ST Segment Elevation Myocardial Infarction Unstable Angina Pectoris Stable Angina Pectoris

COMPLETED PHASE4

Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI

NCT01033058

STEMI

UNKNOWN PHASE4

The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation

NCT00579098

Atrial Fibrillation Arrhythmia Inflammation +1 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To date, there have been no studies that prospectively and systemically evaluated the efficacy and safety of STAR with deferred stenting and described the frequency of its use in the hybrid approach. The aim of this study is to address these current gaps in knowledge, including the frequency of use of STAR by experienced operators, the safety of its use, optimal timing of staged stenting and health status change associated with this procedure. This prospective study will enroll 150 patients undergoing elective PCI of native CTO utilizing the STAR technique and will subsequently randomize patients in a 1:1 fashion to early (5-7 weeks) and later (12-14 weeks) timing of subsequent stenting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Occlusion Coronary Stenosis Coronary Restenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early stent placement

Stent placement 5-7 weeks post-STAR procedure

Group Type OTHER

Stent Placement Timing - Early

Intervention Type OTHER

Stent placement 5-7 weeks after STAR procedure

Later stent placement

Stent placement 12-14 weeks post-STAR procedure

Group Type OTHER

Stent Placement Timing - Late

Intervention Type OTHER

Stent placement 12-14 weeks after STAR procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stent Placement Timing - Early

Stent placement 5-7 weeks after STAR procedure

Intervention Type OTHER

Stent Placement Timing - Late

Stent placement 12-14 weeks after STAR procedure

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is scheduled for a PCI procedure for at least one chronic total occlusion with TIMI antegrade flow of zero.
2. Subject is ≥ 18 years of age at the time of consent
3. The operator attempted STAR technique defined as knuckle guidewire across or into the CTO segment during the CTO PCI and is planned for a staged procedure.
4. English speaking due to follow up.

Exclusion Criteria

1. The CTO segment is in a graft.
2. Female subjects with a positive quantitative or qualitative pregnancy test, in accordance with hospital policy.
3. Unable to participate in telephone follow-up

1. Too hard of hearing to do follow-up by telephone or deaf.
2. Incarcerated prisoner.
3. History of dementia.
4. Subjects without a way for contact by telephone for follow-up.
4. Previously enrolled in STAR.
5. Patient not a candidate for baseline and final angiography (CKD with eGFR\<30).
6. The knuckled guidewire did not cross into the CTO segment during STAR attempt.
7. A stent was placed into the STAR segment during the Index Procedure.
8. Refused participation in the study.
9. Patient enrolled in another study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No